-
Mashup Score: 18
The microbiome can identify those who benefit from combination immunotherapy across multiple different cancers, including rare gynecological cancers, biliary tract cancers and melanoma.
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 37New drug could unlock benefits of immunotherapy for more patients - 2 month(s) ago
A new drug could offer a powerful way to sensitise tumours to immunotherapy, a new trial suggests.
Source: www.icr.ac.ukCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Immunotherapy Combo Key to Treating Some Liver Tumors - 2 month(s) ago
Abstract: Combining the PD-L1 inhibitor durvalumab and the angiogenesis inhibitor bevacizumab with transarterial chemoembolization can prolong progression-free survival in patients with inoperable hepatocellular carcinoma. However, ongoing trials may reveal an even more effective combination of checkpoint inhibitor with VGEF inhibitors plus TACE therapy for patients with liver cancer.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 49FDA Approves Toripalimab for Advanced Nasopharyngeal Cancer - 3 month(s) ago
Adding toripalimab (Loqtorzi) to chemo extended survival in people with nasopharyngeal cancer that returned after initial treatment or spread in the body.
Source: www.cancer.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Immunotherapy Combo Key to Treating Some Liver Tumors | Cancer Discovery News | American Association for Cancer Research - 3 month(s) ago
Abstract: Combining the PD-L1 inhibitor durvalumab and the angiogenesis inhibitor bevacizumab with transarterial chemoembolization can prolong progression-free survival in patients with inoperable hepatocellular carcinoma. However, ongoing trials may reveal an even more effective combination of checkpoint inhibitor with VGEF inhibitors plus TACE therapy for patients with liver cancer. DOI: https://doi.org/10.1158/2159-8290.CD-NB2024-0003 You do not currently have access to this content. Don’ t already
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 26Decoding the Autoantibody âReactomeâ in Cancer Immunotherapy | The Mark Foundation for Cancer Research - 3 month(s) ago
This project explores the diverse effects of autoantibodies on cancer immunotherapy outcomes, seeking to understand why patients respond so differently to treatment. Using a new antibody profilingâŠ
Source: themarkfoundation.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 19
Abstract. The field of oncology has been transformed by immune checkpoint inhibitors (ICI) and other immune-based agents, however many patients do not receive a durable benefit. While biomarker assessments from pivotal ICI trials have uncovered certain mechanisms of resistance, results thus far have only scraped the surface. Mechanisms of resistance are as complex as the tumor microenvironment (TME) itself, and the development of effective therapeutic strategies will only be possible by building accurate models of the tumor-immune interface. With advancement of multi-omic technologies, high-resolution characterization of the TME is now possible. In addition to sequencing of bulk tumor, single-cell transcriptomic, proteomic, and epigenomic data as well as T cell receptor profiling can now be simultaneously measured and compared between responders and non-responders to ICI. Spatial sequencing and imaging platforms have further expanded the dimensionality of existing technologies. Rapid a
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Congrats @RyanAugustinMD @wesleylcai & field-leading comp bio collaborator @ImmunoTiil @RiyueSunnyBao on overview of multi-dimensional biomarker, omics & translational investigations to adv combo #immunotherapy. Field moving fast so get wise or get lost! https://t.co/sNVXRa4sPv https://t.co/a6UAiWSpZO
-
-
Mashup Score: 17Decoding the Autoantibody âReactomeâ in Cancer Immunotherapy | The Mark Foundation for Cancer Research - 3 month(s) ago
This project explores the diverse effects of autoantibodies on cancer immunotherapy outcomes, seeking to understand why patients respond so differently to treatment. Using a new antibody profilingâŠ
Source: themarkfoundation.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4The Art of Immunotherapy - 4 month(s) ago
Selection of a patient with rhinitis/conjunctivitis or asthma for allergy immunotherapy (AIT) requires several decisions. First, does the patientâs sensitization, pattern of exposure to an allergen, and degree of exposure to that allergen reasonably suggest a causal relationship? Does the level and duration of symptoms warrant the cost and inconvenience of immunotherapy, or is the patient motivated by the disease-modifying potential of AIT? If AIT is selected, is the choice to be greater safety and convenience with sublingual immunotherapy (SLIT) tablets, but with treatment probably limited to 2 or 3 allergens, or for subcutaneous immunotherapy where multiple allergen therapy is the rule and efficacy may be somewhat greater, at least initially, or does the physician go off-label into the unknowns of liquid SLIT? Are there extracts of sufficient potency to achieve likely effective doses? How does the physician deal with large local or systemic reactions, with gaps in treatment, with pol
Source: www.jaci-inpractice.orgCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 2Courtney | Leukemia and Lymphoma Society - 4 month(s) ago
In March 2022, I began experiencing unusual symptoms of fatigue, nausea, persistent infections, and bloody noses and gums, but I didnât think much of it. Following a lucky-timed appointment with my primary care doctor and multiple blood tests, I was diagnosed with acute lymphoblastic leukemia (ALL). Cancer isnât something an otherwise âhealthyâ 27-year-old thinks will come out of a doctorâs mouth. Just hours after I first heard the âc-word,â I was admitted inpatient to a cancer center, and just two days later, I began chemotherapy. My initial treatment plan consisted of eight rounds of high-intensity chemotherapy, 12 intrathecal chemotherapy lumbar punctures, oral targeted therapy, and further down the line a stem cell transplant. The chemotherapy rounds dragged on, they were severe, brutal, and isolating. Following three rounds of chemotherapy, I was determined that there had to be another way and sought out a second opinion. Thanks to the dedication of some amazing, daring medical pr
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet
New microbiome insights could help boost #immunotherapy for a range of rare cancers @NatureMedicine https://t.co/KCKc0l1VlZ